5. TERBUTALINE SULFATE

a) Pharmacology
   (1) Stimulates beta-2 receptors located in the smooth muscle of bronchioles
   (2) Causes relaxation of bronchospasm

b) Pharmacokinetics
   Relieves bronchospasm in acute and chronic airway disease with minimal cardiovascular effect

c) Indications
   (1) Asthma
   (2) Reversible airway obstruction associated with bronchitis or emphysema

d) Contraindications
   (1) Patients under 12 years of age

e) Adverse Effects
   (1) Tachycardia
   (2) Palpitations
   (3) Nervousness
   (4) Tremors
   (5) Dizziness
   (6) Nausea
   (7) Vomiting

f) Precautions
   (1) Exercise caution when administering to patients with hypertension or cardiac history
   (2) Monitor EKG

g) Dosage
   (1) Patients 12 years of age and older:
      Administer 0.25 mg IM. May repeat one time after 15 minutes if there is not adequate improvement. Maximum total dose 0.5 mg IM.
   (2) Patients less than 12 years of age: Not indicated

Updated: April 9, 2020